Skip to content

Risk-Score Guided Estimation of Absolute Benefit From Beta-blockers after Myocardial Infarction in Patients Without Heart Failure.

Sep 2026 · European Heart Journal - Quality of Care and Clinical Outcomes · 0 citations
Medicine

TL;DR

The modified TRS-2P stratified baseline risk and provided estimates of absolute beta-blocker benefit, supporting further evaluation of individualized, risk-guided treatment after MI in patients with LVEF ≥40%.

Abstract

Aims

To assess whether a modified clinical risk-score can stratify baseline risk and estimate expected absolute benefit from beta-blocker therapy in post-MI (myocardial infarction) patients with LVEF (left ventricular ejection fraction) ≥40%.

Methods

This substudy of the BETAMI-DANBLOCK trial included patients with a recent MI and LVEF ≥40% who were randomized to beta-blocker or no beta-blocker therapy. A modified Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention (TRS-2P) was constructed, and patients were categorized as low-, intermediate-, or high-risk. The primary outcome was a composite of all-cause mortality, new-MI, unplanned coronary revascularization, ischemic stroke, heart failure, or malignant ventricular arrhythmia. Treatment effects across TRS-2P strata were estimated using Cox proportional hazards and Fine-Gray subdistribution hazard models. Three-year absolute risk reduction (ARR) and number needed to treat (NNT) were calculated for each risk stratum.

Results

Among 5558 patients, 38.4% were classified as low-risk, 52.8% as intermediate-risk, and 8.8% as high-risk. Event rates increased stepwise with higher modified TRS-2P, with no evidence of heterogeneity in the relative treatment effects across risk-strata (hazard ratios: 0.88, 0.81 and 0.88, respectively). However, the score translated the modest relative effects into clinically distinct absolute benefits: Three-year ARR was 1.4% (NNT=72 [95% CI: 41 to 361]) in low-risk, 2.1% (NNT=47 [95% CI: 27 to 239]) in intermediate-risk, and 3.6% (NNT=28 [95% CI: 16 to 140]) in high-risk patients.

Conclusions

The modified TRS-2P stratified baseline risk and provided estimates of absolute beta-blocker benefit, supporting further evaluation of individualized, risk-guided treatment after MI in patients with LVEF ≥40%.

View source

Similar papers

Open access Oct 2026

BETA-BLOCKER THERAPY AFTER MYOCARDIAL INFARCTION IN PATIENTS WITHOUT HEART FAILURE: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

Beta-blocker (BB) therapy after myocardial infarction (MI) in patients with reduced left ventricular ejection fraction (LVEF) is well established. However, recent randomised controlled trials (RCTs) in post-MI patients without significantly impaired LVEF have yielded conflicting results. This meta-analysis aimed...

I. F. Arba, A. Primiputri, M. B. A. Paramarta et al. · 0 citations
Review Aug 2026

Discontinuation of β-blockers in stable patients with previous myocardial infarction, preserved left ventricular ejection fraction, and no heart failure: a pooled analysis of individual patient data.

In stable patients with previous myocardial infarction, left ventricular ejection fraction ≥40%, no heart failure, and no other indication for β-blocker therapy, discontinuation met the non-inferiority criteria for the primary and key secondary endpoints.

J. Silvain, Ki H. Choi, Victorien Monguillon et al. · 1 citation
Open access Aug 2026

Beta-Blocker Use After Acute Myocardial Infarction

Among patients with AMI complicated by HF, in-hospital BB use was associated with lower 1-year adverse outcomes risk in HFrEF/HFmrEF, but not in HFpEF.

Tian-Shu Gu, Su-Tao Hu, Yu-Kun Zhang et al. · 0 citations
Review Sep 2026

Impact of beta-blockers on cardiovascular outcomes in myocardial infarction patients with preserved or mildly reduced ejection fraction: Systematic review and meta-analysis of randomized trials.

In this meta-analysis of randomized clinical trials, beta-blocker use was not associated with a significant reduction in the primary composite outcome or in mortality or reinfarction, and should be interpreted with caution in the context of an overall neutral result.

L. D. Neira-Chunga, D. Moncada-Gutiérrez, G. Vásquez-Tirado et al. · 0 citations
Open access Oct 2026

Prognostic Value of the Non-HDL-C/HDL-C Ratio for Predicting One-Year Major Adverse Cardiac and Cerebrovascular Events in Young Patients with Myocardial Infarction.

OBJECTIVE Young patients with myocardial infarction (MI) remain at risk for recurrent cardiovascular events despite favorable short-term outcomes. The prognostic significance of the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol (non-HDL-C/HDL-C) ratio in this population remains insuff...

M. Keten, Kadir Bıyıklı · 0 citations
Open access Sep 2026

A Cumulative Electrical Risk Score Is Associated with Appropriate ICD Therapy in Primary-Prevention Patients with Reduced Ejection Fraction: A Single-Center Retrospective Study

A cumulative electrical risk score from the standard electrocardiogram was independently associated with appropriate ICD therapy and may add risk information beyond LVEF and warrant prospective, multicenter validation.

Muhammed Rıdvan Ersoysal, Rauf Avcı, Fatih Han Kumtaş et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.